Nabriva Therapeutics
Nabriva Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of anti-infective agents for serious infections, with key products including XENLETA® and CONTEPO™.
Overview of Nabriva Therapeutics
Nabriva Therapeutics is a commercial-stage biopharmaceutical company dedicated to the development of innovative anti-infective agents for the treatment of serious infections. The company operates in the United States, Austria, and Ireland. Nabriva is committed to providing new and effective treatments for patients afflicted with challenging infections.
XENLETA® (Lefamulin)
Nabriva Therapeutics' XENLETA® (lefamulin) is an innovative anti-infective agent designed to treat community-acquired pneumonia (CAP). XENLETA® was approved by the FDA for both oral and IV administration on August 19, 2019. Furthermore, the European Medicines Agency approved XENLETA® on July 28, 2020, for the same indication. Nabriva also provides a Named Patient Program to supply XENLETA® to healthcare professionals in certain countries where it is not yet available.
Partnership with Sunovion Pharmaceuticals
In an effort to expand its market reach, Nabriva Therapeutics entered into a license and commercialization agreement with Sunovion Pharmaceuticals Canada Inc. for XENLETA® in Canada. This partnership is part of Nabriva's strategy to provide innovative treatments for serious infections across global markets.
Development of CONTEPO™
Nabriva Therapeutics is actively developing CONTEPO™ (fosfomycin for injection), a potentially first-in-class epoxide antibiotic aimed at treating complicated urinary tract infections, including acute pyelonephritis. The company has submitted a New Drug Application for CONTEPO™ in the United States. However, the FDA issued a Complete Response Letter due to the agency's inability to conduct onsite inspections because of travel restrictions.
Collaborations and Licensing Opportunities
Nabriva Therapeutics seeks to advance its mission through strategic collaborations and licensing opportunities. The company focuses on the discovery, development, and commercialization of technologies and therapies that address infectious diseases. These partnerships are vital for Nabriva in enhancing its product pipeline and expanding its capabilities in the anti-infective treatment space.